Cetuximab-platinum chemotherapy is used for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC); however, a minority of patients benefit. Gene expression profiling (GEP) of HNSCCs with prolonged responses to cetuximab-chemotherapy demonstrate basal subtype traits including signatures of EGFR signaling and hypoxic differentiation. GEP of short-response patients show RAS activation. Clin Cancer Res; 22(15); 1-3. ©2016 AACR.See related article by Bossi et al., p. 3961.
Mendeley saves you time finding and organizing research
Choose a citation style from the tabs below